2. >
  3. Investors
  4. >
  5. Regulated Information
  6. >
  7. Press Releases – Reg...

PRESS RELEASES

Found 286 Results
Page 3 of 29

Onxeo Announces its Financial Agenda for 2021


Paris (France), January 7, 2021 – 6 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]

01/07/2021

Onxeo Announces the Transfer of the Listing of its Shares to Euronext Growth Paris on December 15, 2020


Paris (France), December 10, 2020 – 6 pm CET – Onxeo S.A. (ISIN: FR0010095596), (“Onxeo” or “the Company”), a clinical-stage […]

12/10/2020

Onxeo Has Applied for Admission to Trading on Nasdaq First North Growth Market Denmark and Delisting from Nasdaq Main Market Copenhagen


Paris (France), November 27, 2020 – 6 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]

11/27/2020

Onxeo Announces Completion of Patient Enrollment in DRIIV-1b Study and Positive Interim Results


The last patient was treated with AsiDNA™ in combination with carboplatin and paclitaxel in this Phase 1b study in patients […]

Tags:

11/09/2020

Onxeo Receives Notice of Intent to Grant a New Patent Enhancing the Protection in Europe of AsiDNA™ Combined with PARP Inhibitors


This new patent protects the method of use of AsiDNA™ in combination with PARP inhibitors in the treatment of HR-proficient […]

Tags:

10/22/2020

Onxeo Announces Enrollment of First Patient in Phase Ib/II Study Revocan


Revocan is designed to evaluate the abrogation by AsiDNA™ of tumor resistance to a PARP inhibitor in relapsed ovarian cancer […]

Tags:

10/21/2020

Publication of the 2020 Half-Yearly Financial Report


Paris (France), September 29, 2020 – 6.00 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO – FR0010095596), (“Onxeo” […]

09/29/2020

Page 3 of 29
Onxeo Announces Completion of Patient Enrollment in DRIIV-1b Study and Positive Interim Results
09-11-2020
Onxeo Receives Notice of Intent to Grant a New Patent Enhancing the Protection in Europe of AsiDNA™ Combined with PARP Inhibitors
22-10-2020
Onxeo Announces Enrollment of First Patient in Phase Ib/II Study Revocan
21-10-2020
Publication of the 2020 Half-Yearly Financial Report
29-09-2020
Onxeo reports its financial results for the first half of 2020 and provides an update on its activities
17-09-2020
Onxeo to Attend Key Investor Conferences and Events in the Second Half of 2020
08-09-2020
Onxeo Receives Notice of Allowance from USPTO for New Patent Strengthening Protection of AsiDNA™ via Systemic Administration in the United States
03-09-2020
Onxeo Reports Publication of Final Results of DRIIV Phase 1 Dose-Escalation Study of AsiDNA™ in Advanced Solid Tumors in the British Journal of Cancer
27-08-2020
Transfer of the listing of Onxeo securities from the Euronext Paris regulated market (compartment C) to the Euronext Growth Paris multilateral trading facility
29-07-2020
Summary of Onxeo’s Liquidity Contract with Kepler Cheuvreux
03-07-2020